Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Hyperglycemia
Interventions: 5% dextrose, Vitamin C, Simvastatin, Sevoflurane; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 35 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Durham, North Carolina • Canton, Ohio

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 12
States / cities: Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more

Conditions: Sjögren's Syndrome
Interventions: BMS-931699, BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Fullerton, California • Palo Alto, California • Sarasota, Florida + 14 more

Conditions: Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions: denosumab, Placebo, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions: Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 60 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more

Conditions: X-linked Hypophosphatemia
Interventions: burosumab, Placebo; Biological · Other
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more

Conditions: Diabetic Neuropathy
Interventions: VEGF; Biological
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Placebo, Eligard 22.5Mg Suspension for Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 120 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Boca Raton, Florida • New York, New York • Madison, Wisconsin

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Facial Pain, Rhinosinusitis
Interventions: Erenumab Prefilled Syringe, Placebo; Drug · Other
Lead sponsor: David Jang, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mosquito-Borne Infectious Diseases
Interventions: AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: EoE, Eosinophilic Esophagitis
Interventions: Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2428757, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Bermuda Dunes, California • Chula Vista, California • Huntington Beach, California + 12 more

Conditions: Anemia
Interventions: placebo, epoetin alpha, Niferex; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 60 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Cranbury, New Jersey • East Brunswick, New Jersey

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: 0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline); Biological · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more

Conditions: Alopecia Areata
Interventions: LAD603, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Ischemic Stroke, Cerebral Stroke
Interventions: Drug: Normal Saline, Sovateltide; Drug
Lead sponsor: Pharmazz, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Active Ulcerative Colitis
Interventions: BG9418 (Interferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more

Conditions: Pain Management
Interventions: Hylenex recombinant , morphine, saline, Saline; Drug · Other
Lead sponsor: HPC Healthcare, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Lakeland, Florida • Tampa, Florida • Temple Terrace, Florida

Conditions: Type 2 Diabetes
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Achondroplasia
Interventions: Navepegritide, Placebo for Navepegritide; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 0 Years to 2 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin

Search by objective public record fields.

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Preventing Osteoporosis Using Denosumab

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

VEGF Gene Transfer for Diabetic Neuropathy

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Effects of Botox in Obstructed Defecation Syndrome

Erenumab for Idiosyncratic Facial Pain

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Mepo for Eosinophilic Esophagitis (EoE) Study

A Study for Patients With Type 2 Diabetes Mellitus

Prevalence and Treatment of Anemia in Rehabilitation Patients

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

A Study of LAD603 in Adults With Alopecia Areata

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia